{"id":"placebo-to-match-teriflunomide","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Since placebos are inert substances, they do not interact with the body in a way that would produce a therapeutic effect. They are used as a control in clinical trials to compare the efficacy of active treatments.","oneSentence":"Placebos do not have a known mechanism of action.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:49.221Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT04586023","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-03-24","conditions":"Relapsing Multiple Sclerosis","enrollment":751},{"nctId":"NCT05147220","phase":"PHASE3","title":"Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2021-12-16","conditions":"Relapsing Multiple Sclerosis","enrollment":1001},{"nctId":"NCT04586010","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-03-17","conditions":"Relapsing Multiple Sclerosis","enrollment":746},{"nctId":"NCT05156281","phase":"PHASE3","title":"Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2021-12-13","conditions":"Relapsing Multiple Sclerosis","enrollment":1011},{"nctId":"NCT04410991","phase":"PHASE3","title":"Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2020-06-11","conditions":"Relapsing Multiple Sclerosis","enrollment":899},{"nctId":"NCT04410978","phase":"PHASE3","title":"Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2020-06-30","conditions":"Relapsing Multiple Sclerosis","enrollment":974},{"nctId":"NCT02201108","phase":"PHASE3","title":"Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2014-07-16","conditions":"Multiple Sclerosis","enrollment":166},{"nctId":"NCT02792231","phase":"PHASE3","title":"Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-08-26","conditions":"Relapsing Multiple Scelrosis","enrollment":955},{"nctId":"NCT02792218","phase":"PHASE3","title":"Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-09-20","conditions":"Relapsing Multiple Sclerosis","enrollment":930},{"nctId":"NCT00622700","phase":"PHASE3","title":"Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-02","conditions":"Multiple Sclerosis","enrollment":618},{"nctId":"NCT02342652","phase":"PHASE1","title":"A Phase 1, 2-Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ASLAN003 in Healthy Elderly Subjects","status":"COMPLETED","sponsor":"ASLAN Pharmaceuticals","startDate":"2014-10","conditions":"Healthy Elderly Subjects (Age ≥55 Years)","enrollment":7}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo to match Teriflunomide","genericName":"Placebo to match Teriflunomide","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}